Mannan-conjugated allergoid (polymerized) Betula pendula parenteral vaccine
Sponsors
CCDRD Cooperative Clinical Drug Research and Development AG, Inmunotek S.L., ClinCompetence Cologne GmbH, Inmunotek S.L.
Conditions
Birch pollen induced allergic rhinitis or rhinoconjunctivitisbirch pollen-induced allergic rhinitis
birch pollen-induced allergic rhinoconjunctivitis
Phase 3
A prospective, randomized, double-blind placebo-controlled multicentre study with mannan-conjugated birch pollen allergoids administered subcutaneously to adolescent and adult patients with birch pollen-induced allergic rhinitis or rhinoconjunctivitis.
CompletedCTIS2023-508013-16-00
Start: 2024-02-26End: 2024-06-28Target: 600Updated: 2024-02-16
A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered subcutaneously to adolescents and adults with birch pollen-induced allergic rhinitis or rhinoconjunctivitis.
CompletedCTIS2024-515717-17-00
Start: 2024-10-28End: 2025-06-27Target: 360Updated: 2025-08-07